Related Experiment Video
Updated: Mar 18, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic viral therapy under type I interferon regulation: Mathematical modeling and analysis
Prathibha Ambegoda1, Hsiu-Chuan Wei2, Sophia R-J Jang3
1Department of Mathematics, Stark State College, North Canton, OH, USA.
Abstract:
We present and analyze a delay differential equation model of oncolytic viral therapy (OVT) that incorporates tumor-immune-virus interactions, type I interferon (IFN-I) dynamics, and a discrete time delay representing the viral infection cycle. Analytical and numerical results reveal that treatment efficacy critically depends on the balance among viral infectivity, IFN-mediated viral suppression, and immune recruitment. In the absence of immune cells, IFN-I can suppress viral replication, while intracellular delay destabilizes tumor-virus coexistence via Hopf bifurcation. When immune response is included, the system exhibits multiple equilibria and rich bifurcation structures, including bistability and codimension-two bifurcation points. Global sensitivity analysis identifies IFN production, IFN-induced immune suppression, viral infectivity, and immune proliferation as key drivers of tumor control. Our results highlight the dual role of IFN-I, which can either promote viral clearance and tumor escape or facilitate viral persistence and improved therapeutic outcome, depending on the context. These findings underscore the importance of personalized strategies that account for IFN signaling, immune strength, and viral dynamics in optimizing OVT efficacy.
Insights
Oncolytic viral therapy (OVT) efficacy depends on balancing viral infectivity, immune response, and interferon (IFN-I) dynamics. Personalized strategies accounting for these factors are crucial for optimizing OVT outcomes in cancer treatment.
Area of Science:
- Mathematical Biology
- Immunology
- Virology
- Oncology
Background:
- Oncolytic viral therapy (OVT) shows promise for cancer treatment.
- Understanding the complex interplay between tumor cells, the immune system, and viruses is critical for OVT efficacy.
- Type I interferon (IFN-I) signaling plays a significant role in antiviral defense and immune modulation.
Purpose of the Study:
- To develop and analyze a delay differential equation model of OVT.
- To investigate the impact of tumor-immune-virus interactions, IFN-I dynamics, and viral infection cycle delays on treatment outcomes.
- To identify key parameters driving tumor control in OVT.
Main Methods:
- Development of a delay differential equation model.
- Analytical and numerical analysis of the model.
- Bifurcation analysis to study system dynamics.
- Global sensitivity analysis to identify key drivers.
Main Results:
- Treatment efficacy is determined by the balance of viral infectivity, IFN-mediated suppression, and immune recruitment.
- Intracellular delay can destabilize tumor-virus coexistence, while immune responses lead to complex dynamics like bistability.
- IFN production, IFN-induced immune suppression, viral infectivity, and immune proliferation are critical for tumor control.
Conclusions:
- IFN-I has a dual role, potentially promoting viral clearance or persistence, influencing therapeutic outcomes.
- The model highlights the importance of considering IFN signaling, immune status, and viral dynamics for personalized OVT strategies.
- Optimizing OVT requires tailored approaches based on individual patient and viral characteristics.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers

